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Should We Use Dexmedetomidine for Sedation in Parturients 
Undergoing Caesarean Section Under Spinal Anaesthesia?
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With the increasing advanced maternal age, the rate of caesarean sections has been increasing year by year, partic-ularly in some Asian countries such as China (1). Regional anaesthesia is usually preferred for caesarean section because it can keep patients in a painless and awake state during the whole process. In addition, regional anaes-
thesia allows the mother to participate in the birth process, thereby avoiding anaesthetic drugs from entering the maternal 
blood circulation and decreasing the adverse effects and risks of general anaesthesia (2). However, parturients after foetal 
extraction may be reluctant to remain awake in an uncomfortable position potentially interfering with the end of surgical 
procedure (usually surgery ends within 20–30 min after the delivery) (3). For this reason, there is a need for improving 
confort of parturients during the caesarean delivery using drugs characterized by minimal haemodynamic and respiratory 
effects. Several agents such as midazolam, ketamine, propofol, remifentanil and dexmedetomidine have been used with this 
aim (4-6). Some recent placebo-controlled studies suggested that α-2 adrenergic agonists have both analgesic and sedative 
properties when used as adjuvants in regional anaesthesia (7). Dexmedetomidine is a α-2 receptor agonist, which is able to 
produce sedation and analgesia without the unwanted vascular effects due to the activation of α-1 receptors (7, 8).
For many years, anaesthesiologists have used dexmedetomidine with caution in parturients because of possible uteroplacen-
tal transfer, which may cause undesirable effects in the baby. However, recent findings show that because dexmedetomidine 
has a high placental retention (0.77 maternal/foetal index) and is highly lipophilic, it does not get transferred to the baby (9).
Some case reports found that dexmedetomidine has no harmful effects during caesarean delivery (10-13). Many cases 
describe the successful use of dexmedetomidine in parturients when regional anaesthesia was contraindicated or refused. 
Moreover, it has been used as an adjunct to labour epidural if pain relief was not satisfactory, without any adverse foetal 
outcomes with the recommended doses (9).
In the current edition of the Journal, Wang et al. (14) showed that to achieve adequate sedation, ED50 and ED95 of the 
loading dexmedetomidine dose were 0.82 and 0.96 µg kg-1, respectively, for caesarean section under spinal anaesthesia.
It was recently revealed that a 0.6-µg kg-1 loading dexmedetomidine dose via intravenous pumping within 10 min before 
caesarean section and an intraoperative maintenance dose of 0.2 µg kg-1 h-1 until the end of the delivery could achieve good 
haemodynamic stability and satisfied sedation at 30 min after administration in 200 patients undergoing spinal–epidural 
anaesthesia (15). Although the study by Jiang et al. (16) randomly assessed different fixed doses of dexmedetomidine (0.2 µg 
kg-1, 0.4 µg kg-1 and 0.6 µg kg-1), to date, no studies have systematically investigated the effective loading dose for inducing 
adequate sedation in parturients undergoing caesarean section under spinal anaesthesia. The study by Wang et al. (15) is 
the first that used a Dixon up-and-down method (16) to calculate ED50 and ED95 of dexmedetomidine loading dose in a 
parturient undergoing spinal anaesthesia for caesarean section. The starting loading dose for the first parturient was 1.0 µg 
kg-1. According to Dixon up-and-down methodology, the loading dose of the subsequent enrolled parturient was increased 
or decreased (step size of 0.1 µg kg-1) according to sedation level achieved in the previous parturient. After the loading dose, 
all parturients received a dexmedetomidine maintenance dose at a rate of 0.3 µg kg-1 h-1. The sedation target (assessed at 
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5 minutes after loading dose) was a Ramsey sedation score 
of 3 or 4, which means a drowsy or asleep patient but still 
able to follow commands. Of note, surgeons, parturients and 
outcome assessors were blind to the loading dose of dexmede-
tomidine. No oversedation (Ramsey score equal to 5) was de-
tected, and no significant differences were found in ephedrine 
use, atropine use and adverse effects between the success and 
fail groups (patients who did not reach an adequate sedation). 
The result of this study is consistent with that of a recent 
literature (15), which indicate that an appropriate loading 
dexmedetomidine dose of 1 µg kg-1 for spinal anaesthesia and 
a consequently low maintenance infusion (0.3 mcg kg-1 h-1) 
should result in adequate sedation with minimal haemody-
namic instability and without delayed recovery.
However, the study has several limitations that were not very 
well addressed in the limitation section. 1) Subarachnoid 
block may alter the dose required for loading and mainte-
nance of adequate sedation without a cardiovascular effect in 
pregnant women. Thus, doses should be theoretically titrated 
according to the individual patient’s need. Moreover, haemo-
dynamic data were not recorded, so there are no data regard-
ing the cardiovascular effects of the drug. 2) The result of this 
study is applicable only to pregnant women who have given 
pharmacokinetic and pharmacodynamic characteristics (e.g. 
fat-free mass, serum albumin level, plasma albumin level, al-
anine aminotransferase activity and increased cardiac output) 
(17). Moreover, analgesia and sedation in parturients are in-
fluenced by serum corticotrophin and beta-endorphin levels 
that have a peak after foetal extraction (18). 3) It may also be 
argued that the selected time point of outcome assessment 
(5 minutes after the loading dose) might have been too early 
to detect the complete effect of the dexmedetomidine dose. 
The reason for this is the higher volume of the distribution of 
parturients and the potentially longer onset of sedation (17). 
The possible difference between the sedation level and vi-
tal signs of participants in the two groups (success and fail 
groups) should be analysed in future controlled trials.
In conclusions, beyond the fact of whether or not to use dexmede-
tomidine, future studies should address the real need for sedation 
after patients undergoing spinal or combine epidural–spinal an-
aesthesia deliver the baby. Because parturients undergoing caesar-
ean section are anxious and nervous until delivery, most of them 
calm down after hearing the first cry or getting together with the 
baby while surgery continues. Thus, do we need to come back to 
old times? If yes, dexmedetomidine, once known for its contrain-
dication (14, 18), appears to be one of the best choices.
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